Role of SNP/haplotype map in gene discovery and drug development: An overview

Drug Development Research

Volumn 62, Issue 2, 2004, Pages 143-150

  Shastry, Barkur S ^a  

^a OAKLAND UNIVERSITY   (United States)

Author keywords

Allele; Association; Gene; Haplotype; Linkage

Indexed keywords

CONTINUING EDUCATION; DISEASE PREDISPOSITION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESEARCH; GENE IDENTIFICATION; GENE MAPPING; HAPLOTYPE; HUMAN; HUMAN GENOME; PREDICTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 9644303301     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10377     Document Type: Review

References (111)

1. Agundez JA, Ledesma MC, Benitez J, Ladero JM, Rodriguez-Lescure A, Diaz-Rubio E, Diaz-Ruhio M. 1995. CYP 2D6 gene and risk of liver cancer. Lancet 345:830-831.
2. Aiko I. 2003. Neuropeptide gene polymorphisms and human behavioral disorders. Nat Rev Drug Discov 2:986-998.
3. Alhenc-Gelas F, Parmentier L, Bisagni A. 2003. Pharmacogenetic and pharmacogenomic studies: impact on drug discovery and drug development. Therapie 58:275-282.
4. Arranz MJ, Kerwin RW. 2003. Advances in pharmacogenetic prediction of antipsychiatric response. Toxicology 192:33-35.
5. Atbanasiou MC, Malhotra AK, Xu CB, Stephens JC. 2002. Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. Psychiatr Genet 12: 89-96.
6. Bader JS. 2001. The relative power of SNPs and haplotypes as genetic markers for association tests. Pharmacogenomics 2: 11-24.
7. Becquemont L. 2003. Clinical relevance of pharmacogenetics. Drug Metab Rev 35:277-285.
8. Bream JH, Ping A, Zhang X, Winkler C, Young HA. 2002. A single nucleotide polymorphism in the proximal IFN-gamma promoter alters control of gene transcription. Genes Immunity 3: 165-169.
9. Breen G. 2002. Novel and alternate SNP and genetic technologies. Psychiat Genet 12:83-83.
10. Cahill P, Bakis M, Hurley J, Kamath V, Nielsen W, Weymouth D, Dupuis J, Doucette-Stamm L, Smith DR. 2003. Exo-proofreading, a versatile SNP scoring technology. Genome Res 13: 925-931.
11. Cao H, Van Der Veer E, Ban MR, Hanely AJ, Zinman B, Harris SB, Young TK, Pickering JG, Hegele RA. 2004. Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type II diabetes mellitus. J Clin Endocrinol Metab 89:898-903.
12. Carlson CS, Eberle MA, Rieder MJ, Smith JD, Kruglyak L, Nickerson DA. 2003. Additional SNPs and linkage disequilibrium analyses are necessary for whole genome association studies in humans. Nat Genet 33:518-521.
13. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Issacs WB, Xu J. 2004. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 64:1997-1999.
14. Chanock S. 2001. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Dis Markers 17:89-98.
15. Collins A, Lonjou C, Morton NE. 1999. Genetic epidemiology of single nucleotide polymorphisms. Proc Natl Acad Sci USA 96:15173-15177.
16. Colomb E, Nguyen TD, Bechetoille A, Dascotte JC, Valtot F, Brezin AP, Berkani M, Copin B, Gomez L, Polansky JR, Garchon HJ. 2001. Association of a single nucleotide polymorphism in the TIGR/Myocillin gene promoter with the severity of primary open angle glaucoma. Clin Genet 60:220-225.
17. Daly AK. 2003. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 17:27-41.
18. Daly MJ, Rious JD, Schaffner SE, Hudson TJ, Lander ES. 2001. High-resolution haplotype structure in the human genome. Nat Genet 29:229-232.
19. Dishy V, Sofowora GG, Xie X-G, Kim RB, Byrne DW, Stein CM, Wood AJJ. 2001. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 345:1030-1035.
20. Dong SL, Wang E, Hsie L, Cao YX, Chen XG, Gingeras TR. 2001. Flexible use of high-density oligonucleotide arrays for single nucleotide polymorphism discovery and validation. Genome Res 11:1418-1424.
21. Donn RP, Shelley E, Ollier WER, Thomson W. 2001. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rhenmat 44:1782-1785.
22. Evans WE, Relling MV. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491.
23. Ferentz AE. 2002. Integrating pharmacogenomics into drug development. Pharmacogenomics 3:453-467.
24. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Lin-cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. 2002. The structure of haplotype blocks in the human genome. Science 296:2225-2229.
25. Gamulin S. 2003. Impact of molecular medicine on pathophysiology, medical practice and medical education. Croat Med J 44: 374-385.
26. Goldstein DB, Tate SK, Sisodiya SM. 2003. Pharmacogenetics goes genomic. Nat Rev Genet 4:937-947.
27. Gut I. 2001. Automation in genotyping of single nucleotide polymorphisms. Hum Mutat 17:475-492.
28. Guttmacher AE, Collins FS. 2002. Genomic medicine: a primer. N Engl J Med 347:1512-1520.
29. Halapi E, Hakonarson H. 2002. Advances in the development of genetic markers for the diagnosis of disease and drug response. Expert Rev Mol Diagn 2:411-421.
30. Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA. 2003. Evidence for genetic linkage between a polymorphism in adenosine 2A receptor and panic disorder. Neuropyschopharmacology 29: 558-565.
31. Hoehe MR, Timmermann B, Lehrach H. 2003. Human inter-individual DNA sequence variations in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol 4:351-378.
32. Hoffstedt J, Andersson LL, Persson L, Isaksson B, Arner P. 2002. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia 45:584-587.
33. Hogeveen KN, Cousin P, Pugeat M, Dewailly D, Soudan B, Hammond GL. 2002. Human sex hormone binding globulin variants associated with hyperandrogenism and ovarian dysfuction. J Clin Invest 109:973-981.
34. Ikeda T, Mabuchi A, Fukuda A, Kawakami A, Yamada R, Yamamoto S, Miyoshi K, Haga N, Hiraoka H, Takatori Y, Kawaguchi H, Nakamura K, Ikegawa S. 2002. Association analysis of single nucleotide polymorphisms in cartilage-specific collagen genes with knee and hip osteoarthritis in the Japanese population. J Bone Mine Res 17:1290-1296.
35. International HapMap Consortium. The International HapMap project. 2003. Nature 426:789-796.
36. Jain KK. 2002. Personalized medicine. Curr Opin Mol Ther 4: 548-558.
37. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. 1993. Inherited amplification of an active gene in the cytochrome P450 CYP 2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl. Acad. Sci USA 90:11825-11829.
38. Johnson GCL, Esposito L, Barratt BJ, Smith AN, Heward J, DiGenova G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RCJ, Payne F, Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E, Tuomilehto J, Gough SCL, Clyton DG, Todd JA. 2001. Haplotype tagging for the identification of common disease gene. Nat Genet 29:233-237.
39. Johnson JA. 2001. Drug target pharmacogenomics: an overview. Am J Pharmacogenom 1:271-281.
40. Jordan B, Charest A, Dowd JF, Blumenstiel JP, Yeh RF, Osman A, Honsman DE, Lander JE. 2002. Genome complexity reduction for SNP genotyping analysis. Proc Natl. Acad. Sci USA 99: 2942-2947.
41. Ke X, Hunt S, Tapper VV, Lawrence R, Stavrides G, Ghori J, Whittaker P, Collins A, Morris AP, Bentley D, Cardon LR, Deloukas P. 2004. The impact of SNP density on fine-scale patterns of linkage disequilibrium. Hum Mol Genet 13: 577-588.
42. Kirchheiner J, Bertilsson L, Brims H, Wolff A, Roots I, Bauer M. 2003. Individualized medicine: implementation of pharmacogenomic diagnostic in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 36(Suppl):S235-S243.
43. Koschinsky ML, Boffa MB, Nesheim ME, Zinman B, Hanley AJG, Harris SB, Cao H, Hegele RA. 2001. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure. Clin Genet 60:345-349.
44. Kristensen VN, Kelefiotis D, Kristensen T, Borresen-Dale AL. 2001. High-throughput methods for detection of genetic variation. Biotechniques 30:318-326.
45. Kruglyak L. 1999. Prospects for whole genome linkage disequilibrium mapping of common disease genes. Nat Genet 22: 139-144.
46. Kruglyak L, Nickerson DA. 2001. Variation is the spice of life. Nat Genet 27:234-236.
47. Kubota T, Horie M, Takano M, Yoshida H, Takenaka K, Watanabe E, Tsuchiya T, Otani H, Sasayama H. 2001. Evidence for a single nucleotide polymorphism in the KCNQ1 potassium channel that underlies susceptibility to life-threatening arrhythmias. J Cardiovas Electrophysiol 12:1223-1229.
48. Kwok P-Y. 2001. Methods for genotyping single nucleotide polymorphisms. Ann Rev Hum Genet 2:235-258.
49. Lai E. 2001. Application of SNP technologies in medicine: lessons learned and future challenges. Genome Res 11:927-929.
50. Lai E, Bowman C, Bansal A, Hughes A, Mosteller M, Roses AD. 2002. Medical application of haplotype-based SNP maps: learning to walk before we run. Nat Genet 32:353.
51. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients. JAMA 279:1200-1205.
52. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, Vercelli D. 2001. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of SP protein binding and enhances transcriptional activity. J Immunol 167:5838-5844.
53. Lohrer HD, Tangen U. 2000. Investigations into the molecular effects of single nucleotide polymorphism. Pathobiology 68: 283-290.
54. Lovlie R, Daly AK, Molven A, Idle JR, Steen VM. 1996. Ultrarapid metabolizers of debrisoquine: characterization and PCR based detection of alleles with duplication of the CYP 2D6 gene. FEBS Lett 392:30-34.
55. Lyon H, Lange C, Lake S, Silverman EK, Randolph AG, Kwiatki D, Rabi BA, Lazarus R, Weiland KM, Laird N, Weiss ST. 2004. IL-10 gene polymorphisms are associated with asthma phenotype in children. Genet Epidemiol 26:155-165.
56. Mancana D, Arranz MJ, Kerwin RW. 2003. Pharmacogenomics of psychiatric drug treatment. Curr Opin Mol Ther 5:642-649.
57. Marth G, Yeh R, Minton M, Donaldson R, Li Q, Duan S, Davenport R, Miller RD, Kwok P-Y 2001. Single nucleotide polymorphisms in the public domain: how useful are they? Nat Genet 27: 371-372.
58. Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Ribble RC, Booze MW, Rogala A, Hauser MA, Zhang FY, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Pericak-Vance MA, Vance JM. 2001. Association of single nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 286:2245-2250.
59. Matsushita M, Miyakawa H, Tanaka A, Hijikata M, Kikuchi K, Fujikawa H, Arai J, Sainokami S, Hino K, Terai I, Mishiro S, Gershwin ME. 2001. Single nucleotide polymorphisms of the mannose-binding lectin are associated with susceptibility to primary biliary cirrhosis. J Autoimmun 17:251-257.
60. McCarthy JJ, Hilfiker R. 2000. The use of single nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18:505-508.
61. McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR, Peroutka SJ, Griffiths LR, Boyd PR, Lea RA, Bhatti SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R, Lewis KF, Yeo AJM, Williams PM, Priest RC, Khan P, Donnelly C, Lumsden SM, O'Sullivan J, See CG, Smart DH, Shaw-Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG, Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF, Dykes C, Humphrey PPA, Roses AD, Purvis IJ. 2001. Single nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics 78:135-149.
62. McClay JL, Sugden K, Koch HG, Higuchi S, Craig IW. 2002. High-throughput single nucleotide polymorphism genotyping by fluorescent competitive allele-specific polymerase chain reaction (SniPTag). Anal Biochem 301:200-206.
63. McDonald OG, Krynetski EY, Evans WE. 2002. Molecular haplotyping of genomic DNA for multiple single nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenet 12:93-99.
64. Muller M. 2003. Pharmacogenomics and drug response. Int J Clin Pharmacol Ther 41:231-240.
65. Nabi R, Serajee FJ, Chugani DC, Zhong H, Huq AH. 2004. Association of tryptophan 2,3 dioxygenase gene polymorphism with autism. Am J Med Genet 125B:63-68.
66. Nakayama T, Soma M, Saito S, Honye J, Yajima J, Rahmutula D, Kaneko Y, Sato M, Uwabo J, Aoi N, Kosuge K, Kunimoto M, Kanmatsuse K, Kokubun S. 2002. Association of a novel single nucleotide polymorphism of the prostacyclin synthase gene with myocardial infarction. Am Heart J 143:797-801.
67. Nebert DW, Jorge-Nebert L, Vesell ES. 2003. Pharmacogenomics and individualized drug therapy: high expectations and disappointing achievements. Am J Pharmacogenom 3:361-370.
68. Nielsen R. 2000. Estimation of population parameters and recombination rates from single nucleotide polymorphisms. Genetics 154:931-942.
69. Nielsen R, Slatkin M. 2000. Likelihood analysis of ongoing gene flow and historical association. Evolution 54:44-50.
70. Oswald LM, McCaul M, Choi L, Yang X, Wand GS. 2004. Catecholo- methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxon: preliminary report. Biol Psychiatry 55:102-105.
71. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka T. 2002. Functional SNPs in the lymphotoxin alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32:650-654.
72. Panguluri RC, Long LO, Chen W, Wang S, Conlibaly A, Ukoli F, Jackson A, Weinrich S, Asaghotu C, Isaacs W, Kittles RA. 2004. Cox-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25:961-966.
73. Park HY, Nabika T, Jang Y, Kwon HN, Cho SY, Masuda J. 2002. Association of G33A polymorphism in the thrombomodulin gene with myocardial infarction. Hypertension Res 25: 384-394.
74. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. 2001. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279.
75. Pirmohamed M, Park BK. 2001. Gentic susceptibility to drug reactions. Trends Pharmacol Sci 22:298-305.
76. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. 2001. Identification of a single nucleotide polymorphism in the TATA of the CYP 2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284: 455-460.
77. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondai G, Bolstad AI, Svennungsson E, Lundberg I, Sturfelt G, Jonssen A, Truedsson L, Lima G, Alcocer-varela J, Jonsson R, Gyllensten UF, Harley JB, Alarcon-Segovia D, Steinsson K, Alarcon-Riquelme ME. 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 32:666-669.
78. Qi XQ, Bakht S, Devos KM, Gale MD, Osbourn A. 2001. L-RCA (Ligation-rolling circle amplification): a general method for genotyping of single nucleotide polymorphisms (SNPs). Nucleic Acids Res 29:U68-U74.
79. Reich DE, Cargill M, Bolk S, Ireland J, Sabeti PC, Richter DJ, Lavery T, Kouyoumijan R, Farhadian SF, Ward R, Lander ES. 2001. Linkage disequilibrium in the human genome. Nature 411:199-204.
80. Reich DE, Schaffner SF, Daly MJ, McVean G, Mullikin JC, Higgins JM, Richter DJ, Lander ES, Altshulter D. 2002. Human genome sequence variation and the influence of the gene history, mutation and recombination. Nat Genet 32:135-142.
81. Riley J-H, Allan CJ, Lai E, Roses A. 2000. The use of single nucleotide polymorphism in the isolation of common disease gene. Pharmacogenomics 1:39-47.
82. Risch N, Merikangas K. 1996. The future of genetic studies of complex human diseases. Science 273:1516-1517.
83. Roses AD. 2002. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev Drug Discov 1:541-549.
84. Ross JS, Ginsburg GS. 2002. Integration of molecular diagnostics with thearapeutics: implications of drug discovery and patient care. Expert Rev Mol Diagn 2:531-541.
85. Sachse C, Brockmoller J, Bauer S, Roots I. 1997. Cytochrome P450 2D6 variants in a Caucasian population: allelic frequency and phenotypic consequences. Am J Hum Genet 60:284-295.
86. Salisbury BA, Pungliya M, Choi JY, Jiang RH, Sun XJ, Stephens JC. 2003. SNP and haplotype variation in the human genome. Mutat Res-Fund Mol Mech Mutagenesis 526:53-61.
87. Schifreen RS, Storts DR, Buller AM. 2002. The challenge of using SNPs in the understanding and treatment of disease. Biotechniques 32:S14-S21.
88. Schulze TG, Zhang K, Chen Y-S, Akula N, Sun F, McMohan FJ. 2004. Defining haplotype blocks and tag single nucleotide polymorphisms in the human genome. Hum Mol Genet 13: 335-342.
89. Shastry BS. 2002. SNP alleles in human disease and evolution. J Hum Genet 47:561-566.
90. Shastry BS. 2003. SNPs and haplotypes: genetic markers for disease and drug response. Int J Mol Med 11:379-382.
91. Sisodiya SM. 2003. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 16:197-201.
92. Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WER, Worthington J, Davis JRE. 2001. Characterization of a prolactin gene polymorphism and its association with systemic lupus erythematosus. Arthritis Rheumat 44:2358-2366.
93. Subramanian S, Kumar S. 2003. Neutral substitution occurs at a faster rate in exons than in non-coding DNA in primate genome. Genome Res 13:838-844.
94. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, Kakizaki S, Sueyoshi T, Negishi M, Miwa M. 2002. Identification of a defect in die UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292: 492-497.
95. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Lida A, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K. 2003. Functional haplotypes of PADI-4 encoding citullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 34:395-402.
96. Tan F-K, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DM, Arnett FC. 2001. Association of fibrillin-1 single nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheumat 44:893-901.
97. Tempfer CB, Schneeberger C, Huber JC. 2004. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 5:57-65.
98. Terra SG, Johnson JA. 2002. Pharmacogenetics, pharmacogenomics and cardiovascular therapeutics: the way forward. Am J Cardiovasc Drugs 2:287-296.
99. Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, Furukawa H, Nagashima M, Yoshino S, Mabuchi A, Sekine A, Saito S, Takahashi A, Tsunoda T, Nakamura Y, Yamamoto K. 2003. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter is associated with rheumatoid arthritis. Nat Genet 35:341-348.
100. Torpet LA, Kragelund C, Reibel J, Nauntofte B. 2004. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med 15:28-46.
101. Tsai FJ, Wu HC, Che HY, Lu HF, Hsu CD, Chen WC. 2003. Association of E-cadherin gene 3'- UTR C/T polymorphism with calcium oxalate stone disease. Urol Int 70:278-281.
102. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, Tencate JW, Mertens K, Vanmourik JA. 1994. Association of idiopathic venous thromboembolism with single point mutation at Arg (506) of factor V. Lancet 343:1535-1536.
103. Wang LZ, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, Kakehi Y, Kakinuma H, Sato K, Nakamura A, Ogawa O, Kato T 2002. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23: 257-264.
104. Weijer C, Miller PB. 2004. Protecting communities in pharmacogenetic and pharmacogenomic research. Pharmacogenomics J 4:9-16.
105. Wen XY, Hegele RA, Wang J, Wang DY, Cheung J, Wilson M, Yahyapour M, Bai Y, Zhuang LH, Skaug J, Young TK, Connelly PW, Koop BF, Tsui LC, Stewart AK. 2003. Identification of a novel lipase gene mutated in Ipd mice with hypertriglyceridemia and associated with dyslipidemia in humans. Hum Mol Genet 12:1131-1143.
106. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, Rao F, Stridsberg M, Smith DW, Mahboubi P, Schork NJ, O'Connor DT, Hamilton BA. 2004. Both rare and common polymorphisms contribute to functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 74: 197-207.
107. Werner M, Harbon N, Gohlke H, Altmuller J, Knapp M, Heinrich J, Wjst M. 2004. Asthma is associated with single nucleotide polymorphisms in ADAM 33. Clin Exp Allergy 34:26-31.
108. Yoshino T, Takeyama H, Matsunaga T. 2001. Single nucleotide polymorphism analysis using a bacterial magnetic peptide microarray. Electrochemistry 69:1008-1012.
109. Zhang H, Jia Y, Cooper JJ, Hale T, Zhang Z, Elbein SC. 2004. Common variants in glutamine fructose-6-phosphate amidotransferase 2 (GFPT 2) gene are associated with type II diabetes, diabetic nephropathy and increased GFPT 2 mRNA level. J Clin Endocrinol Metab 89:748-755.
110. Zhao LP, Li SYS, Khalid N. 2003. A method for the assessment of disease association with single nucleotide polymorphism haplotypes and environmental variables in case-control studies. Am J Hum Genet 72:1231-1250.
111. Zhu Y, Spitz MR, Lei L, Mills GB, Wu XF. 2001. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61: 7825-7829.